Aethlon Medical director granted 21,815 RSUs

BROENNIMAN EDWARD G reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

BROENNIMAN EDWARD G reported acquisition or exercise transactions in this Form 4 filing.

Aethlon Medical Inc director Edward G. Broenniman reported an equity award of 21,815 shares of Common Stock at $2.29 per share. The award is in the form of RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, subject to his continued service with the company on each vesting date. Following this grant, he directly holds 23,454 shares of Aethlon Medical common stock.

Insider Trade Summary

Grant/Award: 21,815 shares

Grant/Award 1 txn

Insider BROENNIMAN EDWARD G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,815	$2.29	$50K

Holdings After Transaction: Common Stock — 23,454 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person was granted RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, subject to the Reporting Person's continued service with the Company on each such vesting date.

Key Figures

RSU grant size: 21,815 shares Grant price per share: $2.29 per share Shares held after grant: 23,454 shares +2 more

5 metrics

RSU grant size 21,815 shares Common Stock award to director on April 17, 2026

Grant price per share $2.29 per share Reported value for RSU award

Shares held after grant 23,454 shares Director’s direct ownership following transaction

Vesting schedule start June 30, 2026 First of four equal quarterly RSU vesting dates

Vesting schedule end March 31, 2027 Final RSU vesting date, subject to continued service

Key Terms

RSUs, vest, quarterly installments, continued service, +1 more

5 terms

RSUs financial

"The Reporting Person was granted RSUs that vest in four equal quarterly installments"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vest financial

"RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026,"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026,"

continued service financial

"subject to the Reporting Person's continued service with the Company on each such vesting date"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aethlon Medical (AEMD) report in this Form 4?

Aethlon Medical reported that director Edward G. Broenniman received an award of 21,815 shares of Common Stock at $2.29 per share. The award is structured as RSUs that vest over time, reflecting stock-based compensation rather than an open-market stock purchase or sale.

How many Aethlon Medical (AEMD) shares did Edward G. Broenniman acquire and at what price?

Edward G. Broenniman was granted 21,815 shares of Aethlon Medical Common Stock at $2.29 per share. This grant is coded as a compensation-related acquisition, not an open-market transaction, and represents an equity award documented in the company’s Form 4 insider filing.

What is the vesting schedule for Edward G. Broenniman’s Aethlon Medical RSU grant?

The RSUs granted to Edward G. Broenniman vest in four equal quarterly installments. Vesting dates are June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, and each tranche depends on his continued service with Aethlon Medical through the applicable vesting date.

How many Aethlon Medical (AEMD) shares does Edward G. Broenniman hold after this RSU grant?

After the reported RSU grant, Edward G. Broenniman directly holds 23,454 shares of Aethlon Medical Common Stock. This figure reflects his direct ownership position immediately following the transaction recorded in the Form 4 and shows his updated stake in the company’s equity.

Is Edward G. Broenniman’s Aethlon Medical transaction a market buy or a compensation grant?

The transaction is a compensation grant, not a market buy. It is coded as an “A” transaction, described as a grant, award, or other acquisition, with footnotes clarifying that the 21,815 shares are RSUs vesting quarterly over 2026–2027, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BROENNIMAN EDWARD G

(Last) (First) (Middle)

11555 SORRENTO VALLEY RD, STE 203

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/17/2026		A		21,815(1)	A	$2.29	23,454	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, subject to the Reporting Person's continued service with the Company on each such vesting date.

	/s/ Edward G. Broenniman by: James B. Frakes, Attorney-in-fact	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)